[go: up one dir, main page]

DK3229810T3 - Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler - Google Patents

Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler Download PDF

Info

Publication number
DK3229810T3
DK3229810T3 DK15860163.3T DK15860163T DK3229810T3 DK 3229810 T3 DK3229810 T3 DK 3229810T3 DK 15860163 T DK15860163 T DK 15860163T DK 3229810 T3 DK3229810 T3 DK 3229810T3
Authority
DK
Denmark
Prior art keywords
analoges
phospholipid
disabling
medicines
cancer
Prior art date
Application number
DK15860163.3T
Other languages
English (en)
Inventor
Jamey P Weichert
Anatoly Pinchuk
Kevin Kozak
Marc Longino
Joseph Grudzinski
Benjamin Titz
Chorom Pak
Nathan Stehle
Original Assignee
Cellectar Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Biosciences Inc filed Critical Cellectar Biosciences Inc
Application granted granted Critical
Publication of DK3229810T3 publication Critical patent/DK3229810T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548Phosphates or phosphonates, e.g. bone-seeking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15860163.3T 2014-11-17 2015-11-06 Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler DK3229810T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462080436P 2014-11-17 2014-11-17
PCT/US2015/059382 WO2016081203A2 (en) 2014-11-17 2015-11-06 Phospholipid ether analogs as cancer-targeting drug vehicles

Publications (1)

Publication Number Publication Date
DK3229810T3 true DK3229810T3 (da) 2020-08-17

Family

ID=55960741

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15860163.3T DK3229810T3 (da) 2014-11-17 2015-11-06 Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
DK20186803.1T DK3750545T3 (da) 2014-11-17 2015-11-06 Phospholipidetheranaloger som cancermålrettede lægemiddelbærere

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK20186803.1T DK3750545T3 (da) 2014-11-17 2015-11-06 Phospholipidetheranaloger som cancermålrettede lægemiddelbærere

Country Status (18)

Country Link
US (4) US9345718B1 (da)
EP (2) EP3229810B1 (da)
JP (1) JP6832861B2 (da)
KR (1) KR102500181B1 (da)
CN (2) CN116655690A (da)
AU (1) AU2015350400B2 (da)
BR (1) BR112017010188B1 (da)
CA (1) CA2968145C (da)
DK (2) DK3229810T3 (da)
EA (1) EA037519B1 (da)
ES (2) ES2978534T3 (da)
IL (1) IL252102B (da)
MX (1) MX381235B (da)
PT (1) PT3229810T (da)
SG (1) SG11201703979QA (da)
SI (2) SI3229810T1 (da)
TW (1) TWI576341B (da)
WO (1) WO2016081203A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037519B1 (ru) * 2014-11-17 2021-04-07 Селлектар Байосайенсиз, Инк. Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
AU2016326392B2 (en) 2015-09-22 2021-02-11 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
CA3004458C (en) * 2015-11-06 2021-03-30 Wisconsin Alumni Research Foundation Long-lived gadolinium based tumor targeted imaging and therapy agents
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Car t細胞療法のための方法および組成物
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11147823B2 (en) 2016-07-13 2021-10-19 Wisconsin Alumni Research Foundation Phospholipid ether analogs for imaging and targeted treatment of pediatric solid tumors
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
KR102396334B1 (ko) 2016-07-18 2022-05-09 위스콘신 얼럼나이 리서어치 화운데이션 인 시츄 면역 조절 암 백신화를 위한 방사성할로겐화 제제
KR102332958B1 (ko) * 2016-07-25 2021-11-29 위스콘신 얼럼나이 리서어치 화운데이션 암 영상화 및 치료를 위한 방사성 인지질 금속 킬레이트
EP3487530B1 (en) 2016-07-25 2024-03-20 Wisconsin Alumni Research Foundation Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
EP3579870A4 (en) * 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
AU2019209432A1 (en) 2018-01-22 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
CN111936518A (zh) * 2018-02-06 2020-11-13 西雅图儿童医院(Dba西雅图儿童研究所) 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
NZ768472A (en) * 2018-04-10 2024-12-20 Cellectar Biosciences Inc Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
EP3937975A4 (en) * 2019-03-13 2023-06-21 Seattle Children's Hospital (DBA Seattle Children's Research Institute) FLUORESCEIN SODIUM AS AN INVERSION AGENT FOR ANTI-FLUORESCEIN CAR-T CELLS AND FLUORESCEIN-PHOSPHOLIPID ETHERS OR PHOSPHOLIPID-PHOSPHOLIPID ETHERS
TWI705813B (zh) 2019-05-24 2020-10-01 國立交通大學 含有ganetespib的粒子與含有該粒子的藥學組成物及其在抗癌治療上的用途
WO2020262609A1 (ja) * 2019-06-27 2020-12-30 昭和電工マテリアルズ株式会社 細胞足場材、細胞培養支持体、及び細胞の培養方法
BR112022004482A2 (pt) * 2019-09-12 2022-05-31 Cellectar Biosciences Inc Conjugados de éter fosfolipídico como veículos de fármacos direcionados ao câncer
EP4041718A4 (en) * 2019-10-10 2023-12-20 Cellectar Biosciences, Inc. PHOSPHOLIPIDE-FLVAGLIN CONJUGATES AND METHOD FOR THE USE THEREOF FOR TARGETED CANCER THERAPY
CA3212963A1 (en) 2021-04-23 2022-10-27 Reinier HERNANDEZ Psma-targeting ligands with optimal properties for imaging and therapy
CN114437128B (zh) * 2022-01-28 2023-12-19 中国科学院长春应用化学研究所 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965391A (en) * 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
DE4408011C1 (de) 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
CA2276284C (en) * 1996-12-04 2006-10-10 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
EP1161226B1 (en) * 1999-02-18 2004-05-26 SuperGen, Inc. Phosphocholine linked prodrug derivatives
IL131887A0 (en) * 1999-09-14 2001-03-19 Dpharm Ltd Phospholipid prodrugs of anti-proliferative drugs
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
ATE437657T1 (de) 2004-03-02 2009-08-15 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
US7632644B2 (en) 2004-03-02 2009-12-15 Cellectar, Inc. Imaging and selective retention of phospholipid ether analogs
CA2572398A1 (en) 2004-07-08 2006-02-09 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs
JP2008545614A (ja) * 2004-12-20 2008-12-18 セレクター、リミテッド ライアビリティ カンパニー 癌の検出および治療のためのリン脂質エーテル類似体
US20070167408A1 (en) 2005-12-19 2007-07-19 Zentaris Gmbh Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
WO2008150439A1 (en) * 2007-06-01 2008-12-11 Cellectar, Inc. Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use
US7893286B2 (en) 2007-06-01 2011-02-22 Cellectar, Inc. Method for the synthesis of phospholipid ethers
KR101563658B1 (ko) * 2007-11-28 2015-10-27 셀라토 파마슈티칼즈, 인코포레이티드 개선된 탁산 전달 시스템
EP2429591B1 (en) * 2009-05-11 2015-08-26 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
US8871181B2 (en) 2009-05-11 2014-10-28 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
US20100286510A1 (en) * 2009-05-11 2010-11-11 Pinchuk Anatoly Use of fluorescent phospholipid ether compounds in biopsies
US20100284931A1 (en) * 2009-05-11 2010-11-11 Pinchuk Anatoly Fluorescent phospholipid ether compounds, compositions, and methods of use
US7811548B1 (en) 2009-05-11 2010-10-12 Cellectar, Inc. Fluorescent phospholipid ether compounds and compositions
SI2440253T1 (sl) 2009-06-12 2020-09-30 Cellectar, Inc. Alkil fosfolipidne spojine za zdravljenje raka in slikanje in detekcijo rakavih izvornih celic
WO2011031919A2 (en) 2009-09-11 2011-03-17 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
WO2013016658A1 (en) 2011-07-27 2013-01-31 The Ohio State University Research Foundation Silvestrol, silvestrol analogs and uses thereof
EA037519B1 (ru) * 2014-11-17 2021-04-07 Селлектар Байосайенсиз, Инк. Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки
ES2870037T3 (es) 2015-11-25 2021-10-26 Effector Therapeutics Inc Compuestos inhibidores de EIF4-A y métodos relacionados con los mismos
CN109476648B (zh) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
NZ768472A (en) 2018-04-10 2024-12-20 Cellectar Biosciences Inc Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Also Published As

Publication number Publication date
EP3750545A1 (en) 2020-12-16
ES2978534T3 (es) 2024-09-13
CN107708702A (zh) 2018-02-16
AU2015350400B2 (en) 2020-11-05
KR20170106304A (ko) 2017-09-20
SI3229810T1 (sl) 2021-01-29
CN116655690A (zh) 2023-08-29
BR112017010188B1 (pt) 2023-03-28
EA037519B1 (ru) 2021-04-07
CA2968145A1 (en) 2016-05-26
DK3750545T3 (da) 2024-04-22
IL252102B (en) 2021-10-31
IL252102A0 (en) 2017-08-31
WO2016081203A2 (en) 2016-05-26
US20160136190A1 (en) 2016-05-19
TWI576341B (zh) 2017-04-01
JP2017535608A (ja) 2017-11-30
KR102500181B1 (ko) 2023-02-14
NZ731669A (en) 2021-02-26
US9480754B2 (en) 2016-11-01
EP3229810A4 (en) 2018-07-25
EA201791094A1 (ru) 2017-09-29
MX2017006382A (es) 2018-04-10
WO2016081203A3 (en) 2016-08-18
US9345718B1 (en) 2016-05-24
EP3750545B1 (en) 2024-03-27
BR112017010188A2 (pt) 2018-02-14
EP3229810A2 (en) 2017-10-18
AU2015350400A1 (en) 2017-05-25
EP3229810B1 (en) 2020-07-22
US9925269B2 (en) 2018-03-27
CA2968145C (en) 2023-06-27
US20160136290A1 (en) 2016-05-19
ES2811367T3 (es) 2021-03-11
US20180333498A1 (en) 2018-11-22
PT3229810T (pt) 2020-08-27
US11439709B2 (en) 2022-09-13
JP6832861B2 (ja) 2021-02-24
SI3750545T1 (sl) 2024-06-28
MX381235B (es) 2025-03-12
TW201619145A (zh) 2016-06-01
SG11201703979QA (en) 2017-06-29
US20160228564A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
BR112016023628A2 (pt) composições farmacêuticas.
DK3199161T3 (da) Farmaceutisk præparat
FR3023988B3 (fr) .
EP3246047C0 (en) COMBINATION MEDICATION
HUE047581T2 (hu) Készítmény
HUE050881T2 (hu) Gyógyszerkészítmény
ES1119860Y (es) Caramelo
TH1601003444B (th) องค์ประกอบทางเภสัชกรรมของแคโรทีนอยด์
UA29067S (uk) Флакон
UA29303S (uk) Пляшка
UA31918S (uk) Пляшка
TH1501003886A (th) น้ำยาทำความสะอาด
UA28861S (uk) Пляшка
TH1601000473A (th) ไมโครแคปซูล (Micropsules)
UA29043S (uk) Пляшка
UA30657S (uk) Пляшка
UA28991S (uk) Пляшка
UA30561S (uk) Пляшка
UA30562S (uk) Пляшка
UA28627S (uk) Пляшка
UA30859S (uk) Пляшка
UA28428S (uk) Пляшка
UA28782S (uk) Пляшка
UA30743S (uk) Пляшка